BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33741354)

  • 21. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
    Fan YX; Wong L; Marino MP; Ou W; Shen Y; Wu WJ; Wong KK; Reiser J; Johnson GR
    J Biol Chem; 2013 Jun; 288(23):16895-16904. PubMed ID: 23612964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.
    Esparís-Ogando A; Díaz-Rodríguez E; Pandiella A
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):339-48. PubMed ID: 10567214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple Grb2-protein complexes in human cancer cells.
    Sastry L; Cao T; King CR
    Int J Cancer; 1997 Jan; 70(2):208-13. PubMed ID: 9009162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.
    Li H; Sánchez-Torres J; Del Carpio A; Salas V; Villalobo A
    Biochem J; 2004 Jul; 381(Pt 1):257-66. PubMed ID: 15080792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel mode of ligand recognition by the Erbin PDZ domain.
    Birrane G; Chung J; Ladias JA
    J Biol Chem; 2003 Jan; 278(3):1399-402. PubMed ID: 12444095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation.
    Wang H; Leavitt L; Ramaswamy R; Rapraeger AC
    J Biol Chem; 2010 Apr; 285(18):13569-79. PubMed ID: 20181947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
    Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
    Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src.
    Suzuki A; Kadota N; Hara T; Nakagami Y; Izumi T; Takenawa T; Sabe H; Endo T
    Oncogene; 2000 Nov; 19(51):5842-50. PubMed ID: 11127814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
    Agus DB; Akita RW; Fox WD; Lewis GD; Higgins B; Pisacane PI; Lofgren JA; Tindell C; Evans DP; Maiese K; Scher HI; Sliwkowski MX
    Cancer Cell; 2002 Aug; 2(2):127-37. PubMed ID: 12204533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs.
    Pinet L; Assrir N; van Heijenoort C
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DDT stimulates c-erbB2, c-met, and STATS tyrosine phosphorylation, Grb2-Sos association, MAPK phosphorylation, and proliferation of human breast epithelial cells.
    Shen K; Novak RF
    Biochem Biophys Res Commun; 1997 Feb; 231(1):17-21. PubMed ID: 9070211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
    Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
    Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.